Potassium Phosphate

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Special Considerations

Brand Names

North America

USA: Neutra-Phos-K.


Japan: Conclyte PK, Dibasic Potassium Phosphate, Dipotassium Phosphate.

Drug combinations

Potassium Phosphate and Sodium Phosphate

Other Potassium Phosphate combinations: Calcium Chloride; Panax ginseng; Sodium Acetate; Sodium Chloride; Sodium Phosphate


Potassium Phosphate, Dibasic: K~2~HPO~4~. Mw: 174.18. Phosphoric acid, dipotassium salt. CAS-7758-11-4.

Pharmacologic Category

Replacement Preparations; Potassium Supplements. Oral Electrolyte Supplement. Parenteral Electrolyte Supplement. (ATC-Code: B05XA06).

Mechanism of action

Therapeutic use

Treatment and prevention of hypophosphatemia.

Pregnancy and lactiation implications

Unlabeled use


Hyperphosphatemia, hyperkalemia, hypocalcemia, hypomagnesemia, renal failure.

Warnings and precautions

Severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (e.g. heart block, ventricular arrhythmias, asystole). Changes in serum potassium concentrations can occur during acid/base correction (use with caution in acid/base alterations). Patients may be more susceptible to life-threatening cardiac effects associated with hyper-/hypokalemia (use with caution in cardiovascular disease (e.g. heart failure, cardiac arrhythmias)). Use with caution in renal impairment, in digitalized patients (may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations), and in patients receiving concomitant medications or therapies which increase potassium (e.g. ACEI, potassium-sparing diuretics, potassium-containing salt substitutes). Oral liquid preparations (not solid) should be used in esophageal compression or delayed gastric emptying. Admixture of phosphate and calcium in I.V. fluids can result in calcium phosphate precipitation. Use extreme caution when administering potassium phosphate parenterally (may cause pain and phlebitis).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart